SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Williams GR)
 

Sökning: WFRF:(Williams GR) > A Roadmap to Gene D...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003493naa a2200469 4500
001oai:prod.swepub.kib.ki.se:147648293
003SwePub
008240701s2021 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1476482932 URI
024a https://doi.org/10.3389/fendo.2021.7097112 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Formosa, MM4 aut
2451 0a A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders
264 c 2021-08-13
264 1b Frontiers Media SA,c 2021
520 a Genetic disorders of the skeleton encompass a diverse group of bone diseases differing in clinical characteristics, severity, incidence and molecular etiology. Of particular interest are the monogenic rare bone mass disorders, with the underlying genetic defect contributing to either low or high bone mass phenotype. Extensive, deep phenotyping coupled with high-throughput, cost-effective genotyping is crucial in the characterization and diagnosis of affected individuals. Massive parallel sequencing efforts have been instrumental in the discovery of novel causal genes that merit functional validation using in vitro and ex vivo cell-based techniques, and in vivo models, mainly mice and zebrafish. These translational models also serve as an excellent platform for therapeutic discovery, bridging the gap between basic science research and the clinic. Altogether, genetic studies of monogenic rare bone mass disorders have broadened our knowledge on molecular signaling pathways coordinating bone development and metabolism, disease inheritance patterns, development of new and improved bone biomarkers, and identification of novel drug targets. In this comprehensive review we describe approaches to further enhance the innovative processes taking discoveries from clinic to bench, and then back to clinic in rare bone mass disorders. We highlight the importance of cross laboratory collaboration to perform functional validation in multiple model systems after identification of a novel disease gene. We describe the monogenic forms of rare low and high rare bone mass disorders known to date, provide a roadmap to unravel the genetic determinants of monogenic rare bone mass disorders using proper phenotyping and genotyping methods, and describe different genetic validation approaches paving the way for future treatments.
700a Bergen, DJM4 aut
700a Gregson, CL4 aut
700a Maurizi, A4 aut
700a Kampe, Au Karolinska Institutet4 aut
700a Garcia-Giralt, N4 aut
700a Zhou, W4 aut
700a Grinberg, D4 aut
700a Crespo, DO4 aut
700a Zillikens, MC4 aut
700a Williams, GR4 aut
700a Bassett, JHD4 aut
700a Brandi, ML4 aut
700a Sangiorgi, L4 aut
700a Balcells, S4 aut
700a Hogler, W4 aut
700a Van Hul, W4 aut
700a Makitie, Ou Karolinska Institutet4 aut
710a Karolinska Institutet4 org
773t Frontiers in endocrinologyd : Frontiers Media SAg 12, s. 709711-q 12<709711-x 1664-2392
856u https://www.frontiersin.org/articles/10.3389/fendo.2021.709711/pdf
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:147648293
8564 8u https://doi.org/10.3389/fendo.2021.709711

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy